Nippon India Pharma Fund - Direct Plan - Growth Plan

Very High Risk
Equity
Sector - Healthcare

NAV as on May 5, 2025

Price per unit of the scheme.

₹ 552.70780.71%1 Day Change

6.12%

Minimum Investment₹5000

Expense Ratio1.03%

FUND RATING

A holistic measure of the rank of a fund relative to its peers. Top funds receive a score of 5.

*Morningstar Rating Methodology i

RISK-O-METER

Level of risk associated with a mutual fund to help investors make informed investment decisions

FUND PERFORMANCE

As On Jan 01, 2023

Compare fund’s performance against category average across different time periods

No Data Found.

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

For calculating Category Return & Scheme Ranking, only Growth & Direct schemes are considered.

FUND COMPARISON

1M 3M 6M 1Y 3Y 5Y

This Fund

Nippon India Pharma Fund - Direct Plan - Growth Plan

Equity: Sector - Healthcare Average NAV

Topper in Equity: Sector - Healthcare

All Fund

No Data Found.

*For the other fund, rescaled NAVs are used

RETURN CALCULATOR

Check the return on your investment in the fund

Nippon India Pharma Fund - Direct Plan - Growth Plan

Investment Type

Monthly Investment

Time Period (yrs)

Annual Return in %

Invested Amount
₹0
Return
₹0

Current Value
₹0

FUND SUMMARY

Benchmark

S&P BSE Healthcare TR INR

Expense Ratio

1.03%

Category Avg Expense Ratio

1.00%

Minimum Investment (Lumpsum/SIP)

₹ 5000 /₹ 100

Lock In (Years)

No Lock-in

Fund Size

₹ 8,080.97 Cr(As on Mar, 2025)

Inception Date

Jan 01, 2013

Turnover

21.00 %

Exit Load

1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units. Nil, thereafter.

Objective: The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund - Direct Plan - Growth Plan is an Equity - Sector - Healthcare fund. The fund was launched inJan 01, 2013. Its risk level is . The NAV of the fund as onMay 05, 2025 is ₹552.71. Its expense ratio is 1.03 %. The fund has an AUM of ₹8,080.97 Cr.The fund is managed bySailesh Raj Bhan,Akshay Sharma,Kinjal Desai.
The minimum initial investment is ₹5000 in Lumpsum mode.

SUBSCRIBE TO

BUSINESS TODAY MAGAZINE

Subscribe Now

Already a subscriber?Login

FUND MANAGER

Sailesh Raj Bhan

Lead Fund Manager.

Apr 1, 2005 - Present

Fund Manager Rank6Out of 10
i
Rank measured on the basis of consistent alpha the fund manager delivered in the same category over a period of three years (factors only Direct plan, Growth option)
Schemes managed3
Total AUM₹ 84,264.01 Cr
Highest Return In 1 Yr16.52 %

Other Funds

table
card

Fund NameMorningstar RatingNAVFund ReturnCategory ReturnRiskFund Size

Nippon India Pharma Fund - Direct Plan - Growth Plan

₹ 552.71

6.12%

2.30%

Very High Risk

₹8,080.97Cr

Nippon India Multi Cap Fund - Direct Plan - Growth

₹ 304.87

6.19%

2.46%

Very High Risk

₹38,636.66Cr

Nippon India Large Cap Fund - Direct Plan - Growth Plan

₹ 96.56

6.77%

3.75%

Very High Risk

₹37,546.38Cr

Nippon India Pharma Fund - Direct Plan - Growth Plan

Very High Risk--

NAV₹ 552.71
Fund Size₹8,080.97Cr

Fund Return6.12%

Category Return2.30%

Nippon India Multi Cap Fund - Direct Plan - Growth

Very High Risk

NAV₹ 304.87
Fund Size₹38,636.66Cr

Fund Return6.19%

Category Return2.46%

Nippon India Large Cap Fund - Direct Plan - Growth Plan

Very High Risk

NAV₹ 96.56
Fund Size₹37,546.38Cr

Fund Return6.77%

Category Return3.75%

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

Akshay Sharma

Lead Fund Manager.

Dec 1, 2022 - Present

Schemes managed51
Total AUM₹ 3,74,070.51 Cr
Highest Return In 1 Yr340.03 %

Other Funds

table
card

Fund NameMorningstar RatingNAVFund ReturnCategory ReturnRiskFund Size

Nippon India Pharma Fund - Direct Plan - Growth Plan

₹ 552.71

6.12%

2.30%

Very High Risk

₹8,080.97Cr

Nippon India Small Cap Fund - Direct Plan - Growth Plan

₹ 174.15

5.31%

0.98%

Very High Risk

₹55,490.73Cr

Nippon India Balanced Advantage Fund Direct Growth Plan

₹ 194.71

3.76%

2.21%

High Risk

₹8,807.55Cr

Nippon India Pharma Fund - Direct Plan - Growth Plan

Very High Risk--

NAV₹ 552.71
Fund Size₹8,080.97Cr

Fund Return6.12%

Category Return2.30%

Nippon India Small Cap Fund - Direct Plan - Growth Plan

Very High Risk

NAV₹ 174.15
Fund Size₹55,490.73Cr

Fund Return5.31%

Category Return0.98%

Nippon India Balanced Advantage Fund Direct Growth Plan

High Risk

NAV₹ 194.71
Fund Size₹8,807.55Cr

Fund Return3.76%

Category Return2.21%

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

Kinjal Desai

Lead Fund Manager.

May 25, 2018 - Present

Schemes managed52
Total AUM₹ 3,74,076.68 Cr
Highest Return In 1 Yr340.03 %

Other Funds

table
card

Fund NameMorningstar RatingNAVFund ReturnCategory ReturnRiskFund Size

Nippon India Small Cap Fund - Direct Plan - Growth Plan

₹ 174.15

5.31%

0.98%

Very High Risk

₹55,490.73Cr

Nippon India Credit Risk Fund Direct Plan Growth Option

₹ 38.01

1.04%

1.72%

High Risk

₹1,001.05Cr

Nippon India Pharma Fund - Direct Plan - Growth Plan

₹ 552.71

6.12%

2.30%

Very High Risk

₹8,080.97Cr

Nippon India Small Cap Fund - Direct Plan - Growth Plan

Very High Risk

NAV₹ 174.15
Fund Size₹55,490.73Cr

Fund Return5.31%

Category Return0.98%

Nippon India Credit Risk Fund Direct Plan Growth Option

High Risk

NAV₹ 38.01
Fund Size₹1,001.05Cr

Fund Return1.04%

Category Return1.72%

Nippon India Pharma Fund - Direct Plan - Growth Plan

Very High Risk--

NAV₹ 552.71
Fund Size₹8,080.97Cr

Fund Return6.12%

Category Return2.30%

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

DETAILED PORTFOLIO

As on Mar, 2025

EQUITY (99.46%)

DEBT (-%)

CASH (0.54%)

Allocation by Market Cap

Large Cap(37.81%)

Mid Cap(33.50%)

Small Cap(28.14%)

Industry Holdings

Drug Manufacturers Specialty Generic66.94%
Diagnostics Research10.62%
Medical Care9.67%
Drug Manufacturers Major8.14%
Pharmaceutical Retailers New3.43%
Biotechnology1.20%

Stock Holdings

Sun Pharmaceuticals Industries Ltd13.43%
Divi's Laboratories Ltd9.28%
Lupin Ltd7.27%
Cipla Ltd5.71%
Apollo Hospitals Enterprise Ltd5.31%
Dr Reddy's Laboratories Ltd5.19%

PERFORMANCE MEASURES

Fund evaluation across critical parameters for better decision making. Study period is 3 years.

Consistency
i
It represents the consistency of a fund in beating its benchmark.
Downside Risk
i
Measured by Maximum Drawdown which shows the maximum loss from a peak to a nadir over a specified time period
Risk Adjusted Return
i
Risk adjusted return represents the return generated after factoring the risk taken to achieve it.
Volatility
i
Volatility represents the standard deviation of fund returns that is, how much the fund returns have deviated from the average.
Upside Capture Ratio
i
Fund performance relative to the index when the market is up. An upside capture ratio of >100 indicates better fund performance.
Downside Capture Ratio
i
Fund performance relative to the index when the market is down. A downside capture ratio of <100 indicates better fund performance.

HISTORICAL RISK MEASURES

Statistical measures to evaluate mutual fund risk. All ratios are calculated for a three-year time duration.

Alpha: Excess return of the fund over benchmark
i
Any Alpha above zero is considered good. However, for comparison, a fund with a higher Alpha is considered better. Alpha is normally used in conjunction with Beta. If the Beta is high, it implies that the fund manager took a high risk to generate Alpha.
2.00
This Fund
VS
0.58
Category Avg
R-Squared: How well the fund tracks benchmark
i
R-Squared measures the correlation of fund returns and its benchmark returns. It varies between 0 and 1. The metric, Beta makes no sense if R-Squared is equal to zero. Thus, both Beta and R-Squared should be used in conjunction. A fund with a high R-Squared and low Beta is considered a less risky fund.
95.16
This Fund
VS
94.87
Category Avg

Beta: Risk of the fund in relation to benchmark
i
Beta >1 indicates that the fund is more volatile than its benchmark while Beta < 1 indicates that the fund is less volatile than its benchmark. The Beta of the benchmark is equal to 1.
0.90
This Fund
VS
0.95
Category Avg
Sharpe Ratio: Risk adjusted return of the fund
i
Sharpe Ratio is a measure of return per unit of risk. A higher Sharpe ratio indicates better risk adjusted return given by the fund.
0.89
This Fund
VS
0.81
Category Avg

Sortino Ratio: Return per unit of bad risk
i
A variation of Sharpe ratio, Sortino considers only the downside risk. Unlike Sharpe ratio which considers both good risk and bad risk, Sortino factors only the bad risk. A high Sortino ratio indicates better return for each unit of downside risk.
1.56
This Fund
VS
1.39
Category Avg
Standard Devation: Volatility of the fund
i
Standard deviation is a measure of dispersion of fund returns from its average return. A fund with a higher Standard deviation is more volatile than a fund with a low standard deviation.
15.81
This Fund
VS
16.73
Category Avg

Benchmark used in calculation : S&P BSE 500 India TR INR

PEER ANALYSIS

card
table

Fund NameMorningstar RatingNAV Fund Return Category ReturnRisk Fund Size

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

TOP FUNDS FROM THIS AMC

card
table

Fund NameMorningstar RatingNAV Fund Return Category Return Risk Fund Size (Cr)

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

ABOUT THE AMC

Nippon Life India Asset Management Ltd

Nippon Life India Asset Management Ltd manages assets worth ₹ 5,67,393.31 crores. It’s current offering of mutual fund schemes includes 31 equity, 78 debt and 12 hybrid schemes.

Phone

022-6808 7000/18602660111

customercare@nipponindiaim.in

AUM

₹ 5,67,393.31 Cr (

As on Mar 31, 2025

)

Address

4th Floor, Tower A, Peninsula Business Park, Mumbai,400 013

FAQ's

What is the category of Nippon India Pharma Fund - Direct Plan - Growth Plan ?

The category of Nippon India Pharma Fund - Direct Plan - Growth Plan is Equity - Sector - Healthcare

What is the current NAV of Nippon India Pharma Fund - Direct Plan - Growth Plan ?

The current NAV of Nippon India Pharma Fund - Direct Plan - Growth Plan as on May 05, 2025 is ₹552.71

How safe is Nippon India Pharma Fund - Direct Plan - Growth Plan ?

The risk level of Nippon India Pharma Fund - Direct Plan - Growth Plan is Very High.

What are short term returns given by Nippon India Pharma Fund - Direct Plan - Growth Plan ?

The return given by Nippon India Pharma Fund - Direct Plan - Growth Plan in 1 month is 6.12%, 3 months is 1.01%, 6 months is -2.52%, and 1 year is 16.52%

What are the long term returns given by Nippon India Pharma Fund - Direct Plan - Growth Plan ?

The return given by Nippon India Pharma Fund - Direct Plan - Growth Plan in 3 years is 22.57% and 5 years is 23.88%.

What is the expense ratio of Nippon India Pharma Fund - Direct Plan - Growth Plan ?

The expense ratio of Nippon India Pharma Fund - Direct Plan - Growth Plan is 1.03%

What is the AUM of Nippon India Pharma Fund - Direct Plan - Growth Plan ?

The assets under Management (AUM) of Nippon India Pharma Fund - Direct Plan - Growth Plan is Rs 8,080.97 crores.

What is the minimum investment in Nippon India Pharma Fund - Direct Plan - Growth Plan ?

The minimum Lumpsum investment in Nippon India Pharma Fund - Direct Plan - Growth Plan is ₹5,000.00 and the minimum SIP investment in Nippon India Pharma Fund - Direct Plan - Growth Plan is ₹100.00

What is the asset allocation of Nippon India Pharma Fund - Direct Plan - Growth Plan?

Nippon India Pharma Fund - Direct Plan - Growth Plan has an exposure of 99.46% in Equity and 0.54% in Cash & Money Market Securities